skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Corrigendum: Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B

Corrigendum

(1322) Views  (2112) Full article downloads

Authors: Scior T, Guevara-Garcia JA, Melendez FJ, et al

Published Date December 2010 Volume 2010:4 Pages 415 - 416
DOI: http://dx.doi.org/10.2147/DDDT.S15892

Error in author list

Dr Melendez was incorrectly affiliated in "Chimeric design, synthesis, and biological assays of a new nonpeptide insulinmimetic vanadium compound to inhibit protein tyrosine phosphatase 1B", published in Drug Design, Development and Therapy.






 

Other articles by Dr Jose Antonio Guevara-Garcia



Readers of this article also read:

Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
ABO and rhesus blood group distribution in Kurds
Safety and efficacy of azacitidine in myelodysplastic syndromes
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B
New approaches in the management of multiple sclerosis
Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University